{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:35:04Z","timestamp":1791282904608,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Royal Society for Tropical Medicine and Hygiene","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-026-26539-6","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:52:41Z","timestamp":1770105161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Viral suppression and adverse events following antiretroviral therapy optimization among children and adolescents in Uganda, 2018\u20132023"],"prefix":"10.1186","volume":"26","author":[{"given":"Collins","family":"Ankunda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Namasambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendah","family":"Kyomuhangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Emunyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Sserunjogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Nakaweesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"26539_CR1","doi-asserted-by":"publisher","unstructured":"Viral load suppression and retention in care among children. and adolescents receiving multi-month anti-retroviral therapy refills: a program data review in Uganda | BMC Pediatrics | Full Text. https:\/\/bmcpediatr.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s12887-024-05295-9. Accessed 5 Nov 2025.","DOI":"10.1186\/s12887-024-05295-9"},{"key":"26539_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/HIV.S509460","volume":"17","author":"JF Inyang","year":"2025","unstructured":"Inyang JF, Sontyo JJ, Bello A, Usman KS, Idaboh TA, Magaji D, et al. Factors impacting viral load suppression in children and adolescents living with HIV enrolled in an orphans and vulnerable children program in Northeast Nigeria. HIVAIDS Auckl NZ. 2025;17:323. https:\/\/doi.org\/10.2147\/HIV.S509460.","journal-title":"HIVAIDS Auckl NZ"},{"key":"26539_CR3","unstructured":"Barriers. and facilitators to HIV viral load suppression among adolescents living with HIV in Lubumbashi, Democratic Republic of the Congo: A qualitative study | PLOS One. https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0320417. Accessed 5 Nov 2025."},{"key":"26539_CR4","unstructured":"HIV - Paediatric care and treatment. UNICEF DATA. https:\/\/data.unicef.org\/topic\/hivaids\/paediatric-treatment-and-care\/. Accessed 5 Nov 2025."},{"key":"26539_CR5","unstructured":"WHO recommends dolutegravir. as preferred HIV treatment option in all populations. https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations. Accessed 5 Nov 2025."},{"key":"26539_CR6","unstructured":"Consolidated Guidelines for Prevention and Treatment of HIV in Uganda | MOH Knowledge Management Portal. https:\/\/library.health.go.ug\/communicable-disease\/hivaids\/consolidated-guidelines-prevention-and-treatment-hiv-uganda. Accessed 5 Nov 2025."},{"key":"26539_CR7","first-page":"142","volume":"February","author":"MoH","year":"2018","unstructured":"MoH. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. Minist Health Uganda. 2018;February:142\u201370.","journal-title":"Minist Health Uganda"},{"key":"26539_CR8","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.2147\/DDDT.S84850","volume":"9","author":"CE Kandel","year":"2015","unstructured":"Kandel CE, Walmsley SL. Dolutegravir \u2013 a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther. 2015;9:3547\u201355. https:\/\/doi.org\/10.2147\/DDDT.S84850.","journal-title":"Drug Des Devel Ther"},{"key":"26539_CR9","volume-title":"StatPearls. Treasure Island","author":"S Thapa","year":"2025","unstructured":"Thapa S, Shrestha U. Immune reconstitution inflammatory syndrome. StatPearls. Treasure Island. (FL): StatPearls Publishing; 2025."},{"key":"26539_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/hiv.13761","volume":"26","author":"EAL Odongpiny","year":"2025","unstructured":"Odongpiny EAL, Nicol M, Katana E, Owori J, Buzibye A, Sedan K, et al. A programmatic assessment of dolutegravir adverse events and discontinuations in Uganda. HIV Med. 2025;26:592\u2013605. https:\/\/doi.org\/10.1111\/hiv.13761.","journal-title":"HIV Med"},{"key":"26539_CR11","unstructured":"Fast-Track. - Ending the AIDS epidemic by 2030 | UNAIDS. https:\/\/www.unaids.org\/en\/resources\/documents\/2014\/JC2686_WAD2014report. Accessed 7 Nov 2025."},{"key":"26539_CR12","unstructured":"The Hospital | Mildmay Uganda. https:\/\/mildmay.or.ug\/hospital. Accessed 8 Aug 2023."},{"key":"26539_CR13","unstructured":"Virological outcomes and genotypic resistance on dolutegravir-based. antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial - The Lancet HIV. https:\/\/www.thelancet.com\/journals\/lanhiv\/article\/PIIS2352-3018(24)00155-3\/fulltext. Accessed 5 Nov 2025."},{"key":"26539_CR14","unstructured":"New findings from. the ODYSSEY trial confirm superiority of dolutegravir-based ART in young children. https:\/\/www.who.int\/news\/item\/16-07-2021-new-findings-from-the-odyssey-trial-confirm-superiority-of-dolutegravir-based-art-in-young-children. Accessed 5 Nov 2025."},{"key":"26539_CR15","unstructured":"Consolidated guidelines for the prevention and treatment of HIV and AIDS in. Uganda, November 2022 | GPC. https:\/\/hivpreventioncoalition.unaids.org\/en\/resources\/consolidated-guidelines-prevention-and-treatment-hiv-and-aids-uganda-november-2022. Accessed 24 Mar 2025."},{"key":"26539_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12981-019-0246-y","volume":"16","author":"B Castelnuovo","year":"2019","unstructured":"Castelnuovo B, Mubiru F, Kalule I, Kiragga A. Reasons for first line ART modification over the years during the ART scale up in Uganda. AIDS Res Ther. 2019;16:31. https:\/\/doi.org\/10.1186\/s12981-019-0246-y.","journal-title":"AIDS Res Ther"},{"key":"26539_CR17","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1080\/21505594.2021.2004743","volume":"12","author":"C Crespo-Bermejo","year":"2021","unstructured":"Crespo-Bermejo C, de Arellano ER, Lara-Aguilar V, Valle-Millares D, G\u00f3mez-Lus ML, Madrid R, et al. Persistent low-Level viremia in persons living with HIV undertreatment: an unresolved status. Virulence. 2021;12:2919\u201331. https:\/\/doi.org\/10.1080\/21505594.2021.2004743.","journal-title":"Virulence"},{"key":"26539_CR18","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.4102\/ajlm.v11i1.1899","volume":"11","author":"N Nanyeenya","year":"2022","unstructured":"Nanyeenya N, Kiwanuka N, Nakanjako D, Nakigozi G, Kibira SPS, Nabadda S, et al. Low-level viraemia: an emerging concern among people living with HIV in Uganda and across sub-Saharan Africa. Afr J Lab Med. 2022;11:1899. https:\/\/doi.org\/10.4102\/ajlm.v11i1.1899.","journal-title":"Afr J Lab Med"},{"key":"26539_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0140-6736(23)00877-2","volume":"402","author":"LN Broyles","year":"2023","unstructured":"Broyles LN, Luo R, Boeras D, Vojnov L. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review. Lancet Lond Engl. 2023;402:464\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(23)00877-2.","journal-title":"Lancet Lond Engl"},{"key":"26539_CR20","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1186\/s12879-025-11607-w","volume":"25","author":"C Ankunda","year":"2025","unstructured":"Ankunda C, Emunyu J, Namasambi S, Sserunjogi C, Kyomuhangi B, Mumbere I, et al. Prevalence of drug resistance mutations and their association with time to virological failure in people living with HIV in Uganda. BMC Infect Dis. 2025;25:1241. https:\/\/doi.org\/10.1186\/s12879-025-11607-w.","journal-title":"BMC Infect Dis"},{"key":"26539_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/QAD.0000000000002854","volume":"35","author":"SM MCCLUSKEY","year":"2021","unstructured":"Mccluskey SM, Kamelian K, MusinguzI N, KigozI S, Boum Y, Bwana MB, et al. Pre-treatment integrase inhibitor resistance is uncommon in ART-na\u00efve individuals with HIV-1 subtype A1 and D infections in Uganda. AIDS Lond Engl. 2021;35:1083\u20139. https:\/\/doi.org\/10.1097\/QAD.0000000000002854.","journal-title":"AIDS Lond Engl"},{"key":"26539_CR22","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s40121-025-01229-9","volume":"14","author":"A Sempere","year":"2025","unstructured":"Sempere A, Alonso R, Berrocal L, Calvo J, Foncillas A, Chivite I, et al. The role of protease inhibitors in HIV treatment: who still needs them in 2025? Infect Dis Ther. 2025;14:2551\u201363. https:\/\/doi.org\/10.1007\/s40121-025-01229-9.","journal-title":"Infect Dis Ther"},{"key":"26539_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/irv.12734","volume":"14","author":"SA Sellers","year":"2020","unstructured":"Sellers SA, Dover KL, Bailey AG, Cheves A, Eason AB, Popowitch EB, et al. Burden of respiratory viral infection in persons with human immunodeficiency virus. Influenza Other Respir Viruses. 2020;14:465\u20139. https:\/\/doi.org\/10.1111\/irv.12734.","journal-title":"Influenza Other Respir Viruses"},{"key":"26539_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jcv.2019.06.006","volume":"117","author":"S Kenmoe","year":"2019","unstructured":"Kenmoe S, Bigna JJ, Fatawou Modiyingi A, Ndangang MS, Ngoupo PA, Simo FBN, et al. Case fatality rate and viral aetiologies of acute respiratory tract infections in HIV positive and negative people in africa: the VARIAFRICA-HIV systematic review and meta-analysis. J Clin Virol. 2019;117:96\u2013102. https:\/\/doi.org\/10.1016\/j.jcv.2019.06.006.","journal-title":"J Clin Virol"},{"key":"26539_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.25259\/JSSTD_48_2020","volume":"3","author":"F Thanveer","year":"2021","unstructured":"Thanveer F. Cutaneous manifestations in primary immunodeficiency diseases. J Skin Sex Transm Dis. 2021;3:143\u201350. https:\/\/doi.org\/10.25259\/JSSTD_48_2020.","journal-title":"J Skin Sex Transm Dis"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-026-26539-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26539-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-026-26539-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:55:27Z","timestamp":1772621727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-026-26539-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["26539"],"URL":"https:\/\/doi.org\/10.1186\/s12889-026-26539-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8074028\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Mildmay Uganda Research Ethics Committee (MUREC) (#REC REF 0201\u20132024) and the Uganda National Council for Science and Technology (HS3873ES). A waiver of informed consent was granted by MUREC for the use of de-identified retrospective data. Administrative clearance was sought from MUgH administration to access participant data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A waiver was granted for publication de-identified retrospective data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"786"}}